CA209-9KU: A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Sep 22, 2026 - P2 | N=60 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2026 ➔ Aug 2027 | Trial primary completion date: Aug 2026 ➔ Aug 2027
Trial completion date • Trial primary completion date • Genito-urinary Cancer • Non Clear Cell Renal Cell Carcinoma • Oncology • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Solid Tumor
|